VisionCare Eye Clinic — Executive Summary

VisionCare Eye Clinic (Pty) Ltd seeks R8.30 million to launch an integrated ophthalmology, optometry, diagnostics and optical-retail centre in Johannesburg — scaling to R48.32 million revenue by Year 5 at a ~32% EBITDA margin and a 31.4% equity IRR.

Section 1 · Business Plan

Executive Summary

VisionCare Eye Clinic (Pty) Ltd is a proposed comprehensive eye-care
centre to be established in the Johannesburg metropolitan area of
Gauteng Province, South Africa, with a phased expansion plan across
major urban centres including Cape Town, Durban, and Pretoria. The
Company will operate as an integrated vision-care destination combining
optometry, ophthalmology, ophthalmic diagnostics, and an optical retail
unit under a single clinical governance framework.

South Africa presents a demonstrably attractive investment
opportunity in private eye-care. The South Africa ophthalmic devices
market alone is projected to reach USD 248.64 million in 2025 and grow
at a compound annual rate of 4.41% to USD 308.52 million by 2030. This
device-market expansion is underpinned by a substantial and rising
disease burden: peer-reviewed meta-analyses show that 12% of the South
African population suffer moderate-to-severe visual impairment, with
uncorrected refractive error (43%), cataract (28%), glaucoma (7%), and
diabetic retinopathy (4%) accounting for the dominant causes. The
diabetic population in particular is a structural demand driver, given
South Africa’s diabetes prevalence among the highest in Sub-Saharan
Africa.

At the same time, approximately 9.7 million South Africans — 15.8% of
the population — are members of one of 73 registered medical schemes,
channelling an estimated R250+ billion annually through private
healthcare. Discovery Health alone covers 2.76 million beneficiaries,
while GEMS, Bonitas, and Momentum together cover a further 2.9 million
lives. This medical-scheme-funded segment is VisionCare’s primary
revenue pool, supplemented by corporate-contract and selective cash-pay
premium business.

1.1 The Opportunity in One Paragraph


The Investment Thesis Private eye-care in South Africa sits at the intersection of three durable tailwinds: (i) an ageing population with cataract and macular-degeneration prevalence rising in lock-step with life expectancy; (ii) a rapidly growing diabetic population exposing ~4.2 million adults to diabetic retinopathy risk; and (iii) chronic under-supply, with the country holding an optometrist-to-population ratio of roughly 1:15,000 and barely 113 public-sector ophthalmologists serving ~52 million uninsured citizens. VisionCare addresses the funded private segment with a differentiated integrated-care proposition that most retail optical chains cannot deliver and most solo ophthalmology practices are too narrow to match.

The Investment Thesis Private eye-care in South Africa sits at the intersection of three durable tailwinds: (i) an ageing population with cataract and macular-degeneration prevalence rising in lock-step with life expectancy; (ii) a rapidly growing diabetic population exposing ~4.2 million adults to diabetic retinopathy risk; and (iii) chronic under-supply, with the country holding an optometrist-to-population ratio of roughly 1:15,000 and barely 113 public-sector ophthalmologists serving ~52 million uninsured citizens. VisionCare addresses the funded private segment with a differentiated integrated-care proposition that most retail optical chains cannot deliver and most solo ophthalmology practices are too narrow to match.

1.2 Business Model Snapshot

VisionCare’s revenue architecture is deliberately diversified across
five streams designed to stabilise cash flow through economic cycles and
produce a blended gross margin of approximately 62% at maturity:

Eye consultations — routine and sub-specialist
consultations priced at R650–R1,200, bulk-billed to medical schemes or
private-pay.
Diagnostic services — OCT scans, visual fields,
corneal topography, fundus photography, and AI-assisted
diabetic-retinopathy screening at R450–R2,500 per modality.
Surgical procedures (Phase 2) — cataract
extraction with IOL implantation, YAG laser capsulotomy, and selected
refractive procedures at R11,000–R28,000 per eye.
Optical retail — frames, prescription lenses,
and contact lenses, with an expected gross margin of 55–65% on
inventory.
Corporate & insurance contracts —
occupational screening, employee-wellness vision days, and
preferred-provider agreements with medical scheme networks.

1.3 Financial Highlights

The Company seeks R 8.30 million (approximately USD 450,000 at
prevailing rates) in combined equity and debt financing to fully
capitalise Phase 1 operations. Under the Base Case, the business
achieves EBITDA positivity in Month 20 and generates Year 5 revenue of R
48.32 million at an EBITDA margin of 32.0%.

R Millions	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	10.80	20.70	30.60	39.74	48.32
Gross Profit	5.72	12.01	18.98	24.64	29.96
EBITDA	(1.35)	2.90	7.35	11.52	15.46
EBITDA Margin %	(12.5%)	14.0%	24.0%	29.0%	32.0%
Net Profit After Tax	(2.10)	1.05	4.50	7.52	10.82

1.4 Capital Request & Use of Funds

Equity financing sought: R 4.50 million (54%) —
promoter contribution R1.50 million and external equity R3.00
million.

Debt financing sought: R 3.80 million (46%) —
commercial term loan, 5-year tenor, prime-linked, secured against
equipment.

1.5 Expected Investor Returns

Under the Base Case, external equity investors are projected to
realise an IRR of 31.4% over a five-year horizon, with a project NPV of
R 12.6 million at a 15% discount rate and a Year-5 equity value in
excess of R 45 million on a 7.0× EBITDA trading-multiple basis. Exit
options are structured around three pathways: strategic sale to a
hospital group (Netcare, Life Healthcare, or Mediclinic),
recapitalisation by a mid-market private-equity fund, or management
buy-out funded by cumulative retained earnings.

The remaining chapters of this plan substantiate these projections
with detailed industry evidence, competitor benchmarking, an
implementation roadmap, comprehensive financial statements, and an
explicit risk-and-mitigation matrix. Each major assumption is tied to a
cited source, stress-tested through sensitivity analysis, and
bench-marked against comparable private-healthcare operating data in
South Africa and adjacent emerging markets.

Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of VisionCare Eye Clinic (Pty) Ltd.